If the DEA reclassifies cannabis and takes it off the schedule-1 drugs list, the FDA could study it for medical uses. This would also allow insurance companies to help patients reduce the cost of medical cannabis, using a co-pay system like the one for pharmacy prescriptions.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.